DiscoveryProbe™ FDA-approved Drug Library: Benchmarking HTS & Drug Repositioning

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) offers 2,320 bioactive compounds, each with established clinical safety and regulatory approval by agencies such as the FDA and EMA (APExBIO). All compounds are provided as pre-dissolved 10 mM solutions in DMSO, stored at -20°C or -80°C for up to 24 months. This collection enables high-throughput screening (HTS) and high-content screening (HCS) for drug repositioning and pharmacological target identification (summary). Representative drugs include doxorubicin, metformin, and atorvastatin, which cover diverse mechanisms of action such as enzyme inhibition and receptor modulation. The library accelerates translational research in oncology, neurodegenerative, and metabolic diseases (Li et al. 2024).

Biological Rationale

Drug discovery increasingly relies on repurposing clinically validated compounds to accelerate target identification and reduce attrition rates. The DiscoveryProbe™ FDA-approved Drug Library (L1021) assembles 2,320 molecules with known pharmacokinetics and safety profiles. Each compound has received approval from major regulatory bodies, including the FDA, EMA, HMA, CFDA, and PMDA, or is listed in recognized pharmacopeias (product page). This diversity supports screening across a breadth of mechanisms: receptor agonists/antagonists, enzyme inhibitors, ion channel modulators, and signaling pathway regulators. The collection enables systematic investigation of cellular processes such as mTORC1 signaling, a master regulator of cell growth implicated in cancer, diabetes, and neurodegeneration (Li et al. 2024). The availability of pre-dissolved, quality-controlled compounds in DMSO further ensures experimental reproducibility and scalability for HTS and HCS platforms.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The library encompasses compounds with a wide range of mechanisms, each confirmed through clinical and preclinical studies. Mechanism classes include:

• Receptor Agonists/Antagonists: Modulate signaling via GPCRs, nuclear receptors, and ion channels (e.g., propranolol, tamoxifen).
• Enzyme Inhibitors: Block catalytic activity of kinases, HDACs, and metabolic enzymes (e.g., doxorubicin, panobinostat).
• Ion Channel Modulators: Alter neuronal and cardiac excitability (e.g., amiodarone, carbamazepine).
• Signal Pathway Regulators: Intervene in pathways such as mTOR, PI3K/AKT, and AMPK, relevant in cancer and metabolic disorders (Li et al. 2024).

Each compound's mechanism is annotated and referenced, enabling targeted screening or discovery of off-target effects for drug repositioning. For example, histone deacetylase inhibitors (HDACi) like panobinostat, present in the library, have been shown to inhibit mTORC1 via nutrient-sensing pathways in live-cell assays (Li et al. 2024).

Evidence & Benchmarks

• All 2,320 compounds are regulatory approved or listed in pharmacopeia, ensuring known safety profiles (APExBIO).
• Pre-dissolved in DMSO at 10 mM, supporting standardized HTS workflows (storage: -20°C for 12 months, -80°C for 24 months) (APExBIO).
• Validated in live-cell mTORC1 inhibition assays using sensors such as TORSEL, confirming pharmacological effects of library HDAC inhibitors (Li et al. 2024, DOI).
• Supports drug repositioning and target identification in oncology and neurodegeneration models (internal article).
• Benchmarked as a reference-standard compound collection in translational research (internal).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is optimized for multiple research domains:

• Cancer Research Drug Screening: Enables rapid identification of known and novel mTORC1 inhibitors (see Li et al. 2024).
• Neurodegenerative Disease Drug Discovery: Facilitates screening for modulators of autophagy and metabolic pathways.
• Drug Repositioning Screening: Empowers discovery of new indications for established drugs (internal).
• Pharmacological Target Identification: Systematic interrogation of cellular signaling cascades using clinically validated molecules.

Despite its breadth, the library has boundaries. It does not cover investigational compounds or chemical probes lacking regulatory status. Screening outcomes depend on assay design and may require orthogonal validation.

Common Pitfalls or Misconceptions

• The library does not contain investigational new drugs (INDs) or experimental chemical probes.
• Results from HTS/HCS screens do not guarantee in vivo efficacy or safety in all models.
• Compound stability is contingent on adherence to specified storage conditions (e.g., -20°C/12 months, -80°C/24 months).
• Not all mechanisms of action are equally represented; some pathways may have limited compound diversity.
• The library is not a substitute for detailed mechanism-of-action validation or clinical trial assessment.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library offers ready-to-use 10 mM DMSO solutions in multiple formats: 96-well microplates, deep well plates, and 2D barcoded screw-top tubes. Compounds are shipped at room temperature or on blue ice depending on user preference. For best results:

• Thaw only required aliquots to minimize freeze-thaw cycles.
• Store at -20°C for up to 12 months or -80°C for up to 24 months (product page).
• Validate hits with orthogonal assays and dose-response curves.
• Combine with live-cell sensors (e.g., TORSEL) to monitor pathway-specific responses during screening (Li et al. 2024).

This library integrates seamlessly with platforms for automated HTS and HCS, supporting both phenotypic and target-based screening strategies (contrast: This article provides updated evidence for live-cell pathway interrogation, extending mechanistic insights beyond what is covered in the strategic overview.).

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) from APExBIO is a robust, validated resource for high-throughput and high-content drug screening. Its comprehensive coverage of clinically approved bioactive compounds enables systematic drug repositioning, rapid pharmacological target identification, and mechanistic interrogation of disease-relevant pathways. Recent advances in live-cell pathway sensors, such as TORSEL for mTORC1, further enhance the library’s utility for translational research (Li et al. 2024). As the landscape of drug discovery evolves, curated libraries like L1021 will remain essential for bridging the gap between bench and bedside.

For detailed specifications and ordering, visit the DiscoveryProbe™ FDA-approved Drug Library product page.